Africa: Leaders Commit to Accelerate Action On Obesity Prevention and Control

Africa: Rwanda Launches Africa’s First Trial of Long-Acting Malaria Prevention Injection

Nairobi — Rwanda has launched Africa’s first clinical trial of a long-acting injectable drug for malaria prevention, marking a potential shift in how the disease is prevented as drug resistance and climate change threaten progress against the mosquito-borne illness. The Phase 1b trial, launched by Medicines for Malaria Venture (MMV) in partnership with Rwandan health…

Read More
Africa: Leaders Commit to Accelerate Action On Obesity Prevention and Control

Africa: Generic HIV Prevention Injection Moves Closer to 120 Countries After FDA Approval

Nairobi — Access to a twice-yearly HIV prevention injection is moving closer to millions of people in low- and middle-income countries after Dr. Reddy’s Laboratories secured tentative approval from the United States Food and Drug Administration (FDA) for the first generic version of lenacapavir. The regulatory milestone, secured just 16 months after approval of Gilead…

Read More
Africa: Leaders Commit to Accelerate Action On Obesity Prevention and Control

Africa: WHO Director-General’s remarks at the High-Level Meeting on Pandemic Prevention, Preparedness and Response – 25 September 2026

New York — Your Excellency Dr Khalilur Rahman, President of the General Assembly, Your Excellency Amar Bendjama, President of ECOSOC, My sister, Deputy Secretary-General Amina Mohamed, The Right Honourable Helen Clark, Excellencies, dear colleagues and friends, Soon after my election as Director-General in 2017, I was invited to speak at an event at Columbia University here in New York…

Read More
Africa: Leaders Commit to Accelerate Action On Obesity Prevention and Control

Africa: AIDS 2026 – Gilead, Governments Must Make HIV Prevention Medicine More Accessible

Brazil has hosted clinical trials paving the way for lenacapavir’s approval and sale, but the medicine remains widely inaccessible for people there. As the 26th International AIDS Conference kicks off this weekend in Rio de Janeiro, Brazil, Doctors Without Borders/Médecins Sans Frontières (MSF) continues to urge the US pharmaceutical corporation Gilead Sciences to make the…

Read More
Africa: Twice-Yearly Lenacapavir Continues to Show Strong HIV Prevention Results

Africa: Twice-Yearly Lenacapavir Continues to Show Strong HIV Prevention Results

Twice-yearly injectable lenacapavir has continued to demonstrate exceptional protection against HIV infection. Twice-yearly injectable lenacapavir continued to provide strong protection against HIV in two landmark clinical trials, with updated data showing almost no new infections, high adherence and no new safety concerns. Researchers said updated findings from the PURPOSE-1 and PURPOSE-2 studies showed the long-acting…

Read More